Furthermore, the reduction in the volume of samples and reagents required provides similar advantages for protein-based assays such as ELISA with limited human and animal serum such as Human Leptin and Endostatin assays.
This DropArray was realized through the efforts of an interdisciplinary team of researchers, which is typical of the project-oriented research at IBN, said Prof Jackie Y. Ying, Executive Director of IBN, one of the 14 research institutes of Singapores Agency for Science, Technology and Research (A*STAR). Prof. Ying was one of the youngest professors at the Massachusetts Institute of Technology, and has received many awards for her research in nanotechnology. She was elected to the German Academy of Natural Scientists, Leopoldina, in April 2005 as the youngest member of the Academy.
IBN was established less than 5 years ago with the mission to conduct exciting scientific research with significant commercial impact. Since then, we have filed more than 420 patents, and we are delighted that our entrepreneurial research team of one chemist, one biologist, one biomedical engineer, one mechanical engineer and one chemical engineer has taken less than three years to develop a novel technology platform that would contribute significantly to reducing the cost of drug development and medication. Curiox Biosystems, the company we set up to market this technology, is IBNs first spin-off.
Nanostart AG, the German-based worlds leading nanotechnology investment company, has invested in Curiox Biosystems, which will further develop and commercialize the DropArray technology. Curiox will be headed by 2 IBN researchers, Dr. Kim Nam Yong, a Korean and Singapore permanent resident who received his Ph.D. in Chemistry from the Massachusetts Institute of Technology, and Dr.
|Contact: Cathy Yarbrough|
Agency for Science, Technology and Research (A*STAR), Singapore